摘要
Prostate cancer is the commonest malignancy to affect men in the United Kingdom. Extraprostatic disease detection at staging and in the setting of biochemical recurrence is essential in determining treatment strategy. Conventional imaging including computed tomography and bone scintigraphy are limited in their ability to detect sites of loco-regional nodal and metastatic bone disease, particularly at clinically relevant low prostate-specific antigen levels. The use of positron emission tomography-computed tomography has helped overcome these deficiencies and is leading a paradigm shift in the management of prostate cancer using a wide range of radiopharmaceuticals. Their mechanisms of action, utility in both staging and biochemical recurrence, and comparative strengths and weaknesses will be covered in this article.
学科与关键词
- Positron Emission Tomography and Computer Tomography (PET/CT) in Prostate, Bladder, and Testicular CancersZouhair, A.*; Ozsahin, M.; Schaffer, M.; Albrecht, S.; Camus, F.; Jichlinski, P.; Mirimanoff, R. -O.; Delaloye, A. Bischof; Meuwly, J. -Y.; Prior, J. O.Current Medicinal Chemistry, 2010, 17(23): 2492-2502.被引 9
- Value of positron emission tomography and computer tomography (PET/CT) for urologic malignanciesBoujelbene, N.; Prior, J. O.; Boubaker, A.; Azria, D.; Schaffer, M.; Gez, E.; Jichlinski, P.; Meuwly, J-Y; Mirimanoff, R. O.; Ozsahin, M.; Zouhair, A.*Cancer Radiotherapie, 2011, 15(4): 307-315.被引 3
- Diagnostic accuracy of 18F-PSMA-1007 PET/CT for prostate 18 cancer in primary staging and biochemical recurrence with different serum PSA levels: A systematic review and meta- analysisLiu, Xue; Wang, Qi; Zhang, Bao; Jiang, Tao*; Zeng, Wenbing*Hellenic Journal of Nuclear Medicine, 2022, 25(1): 88-102.被引 4
